Table 1.
Patient characteristics at initiation of anti-TNF therapy
| Baseline characteristics | nr-axSpA, n = 86 | AS, n = 238 | P valuea |
|---|---|---|---|
| Male sex, n (%) | 53 (62) | 180 (76) | 0.013 |
| Age, years | 38 (13) | 43 (12) | <0.001 |
| Disease duration, years | 9 (9) | 16 (12) | <0.001 |
| Peripheral arthritis, n (%) | 39 (45) | 118 (50) | 0.501 |
| VAS global, mm | 60 (19) | 61 (22) | 0.313 |
| VAS pain, mm | 60 (22) | 62 (22) | 0.292 |
| Evaluator’s global, score 0–4 | 1.7 (0.6) | 2.0 (0.7) | 0.001 |
| BASDAI score | 5.3 (1.7) | 5.4 (1.9) | 0.727 |
| BASFI score | 4.1 (2.3) | 4.3 (2.1) | 0.503 |
| ESR, mm/h | 23 (21) | 28 (23) | 0.026 |
| CRP, mg/l | 10 (13) | 23 (26) | <0.001 |
| Elevated CRP, n (%)b | 47 (58) | 177 (81) | <0.001 |
| EQ-5D (UK) | 0.381 | ||
| Mean (SD) | 0.43 (0.32) | 0.45 (0.33) | |
| Median (IQR; range) | 0.59 (0.64; –0.22 to 0.80) | 0.62 (1.3; –0.48 to 0.80) | |
| Concomitant DMARD (%) | 29 (34) | 150 (63) | <0.001 |
| Previous DMARDs (n) | 0.8 (0.9) | 1.5 (1.0) | <0.001 |
| First anti-TNF agent used, n (%) | <0.001c | ||
| Infliximab | 19 (22) | 112 (47) | |
| Etanercept | 37 (43) | 89 (37) | |
| Adalimumab | 20 (23) | 37 (16) | |
| Golimumab | 7 (8) | 0 (0) | |
| Certolizumab pegol | 3 (4) | 0 (0) |
Mean (SD) if not otherwise stated. Missing data in the non-radiographic axial spondyloarthritis (nr-axSpA)/ankylosing spondylitis (AS) groups, n (%) as follows: Disease duration 1(1)/0(0); visual analog scale (VAS) global 7(8)/24(10); VAS pain 7(8)/24(10); Evaluator’s global 2(2)/18(8); Bath ankylosing spondylitis disease activity index (BASDAI) 36(42)/105(44); Bath ankylosing spondylitis functional index (BASFI) 35(41)/108(45); erythrocyte sedimentation rate (ESR) 4(5)/19(8); C-reactive protein (CRP) 5(6)/20(8); EuroQ ol 5-Dimensions (EQ-5D) 40(47)/60(25); Concomitant disease-modifying anti-rheumatic drug (DMARD) 1(1)/1(0.4). aχ2 for categorical and Mann–Whitney U test for continuous variables. bCRP >3.0 mg/l. cFisher’s exact test